ABSTRACT: Stress adaptation is fundamental for health, and the hypothalamic-pituitary-adrenal axis (HPA) is one of its main mechanisms. Considerable data indicate that arginine vasopressin (AVP) ...

About the Nelivabon Program The Nelivabon program is focused on developing BH-200, a vasopressin V1b receptor antagonist, to treat Major Depressive Disorder (MDD) related to dysfunction in the human ...

The hypothalamic-pituitary-adrenal axis — more commonly referred to as the HPA axis is a major neuroendocrine system that is the originating source of the body’s innate stress response.

The Olive trial is a crucial component of the Nelivabon program, aimed at developing BH-200, a potent vasopressin V1b receptor antagonist, for improved treatment of patients with MDD who have ...

The classical model of the vital increase in systemic glucocorticoid availability is one of an activated hypothalamus-pituitary-adrenocortical (HPA) axis (Figure 1 ... together with vasopressin (AVP), ...

HPA axis dysregulation results in downstream physiological consequences ... ARNT2, Aryl hydrocarbon receptor nuclear translocator 2; AVP, Arginine Vasopressin; BNST, Bed n. of the stria terminalis; ...

Stress-induced hypothalamic activation triggers a cascade involving the pituitary and adrenal glands known as the HPA axis. Under stress, the hypothalamus synthesizes CRF (corticotropin-releasing ...

The HPA axis is dysregulated in chronic stress and psychiatric disorders ... hypothalamic neuropeptides that modulate the secretion of ACTH, such as arginine vasopressin (AVP). AVP is released in ...

France This article reviews some preclinical and clinical studies focusing on the HPA axis hormones and receptors as potential targets for AD. Promising results are obtained by targeting corticotropin ...